First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Study Number
3705523
Phase
I
Age Group
Adult
Principal Investigator
Christos Fountzilas
Purpose

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer

Check your eligibility for this trial
Check now
Full Title

A PHASE 1, FIRST IN HUMAN, DOSE-ESCALATION STUDY OF TORL-3-600 IN PARTICIPANTS WITH ADVANCED CANCER

ClinicalTrials.Gov ID
NCT05948826

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.